Abstract
  • Population : Immunocompetent children aged 3–24 months
  • Intervention: One or two doses of MenA conjugate vaccine (5 µg dosage)
  • Comparison: No MenA vaccination
  • Outcome : Serogroup A meningococcal disease

What is the evidence of long-term protection against serogroup A meningococcal disease following vaccination with one or two doses of MenA conjugate vaccine in immunocompetent children aged 3–24 months?

  • GRADE table
  • Newborn (0-1 years)
  • GRADE
  • Meningococcal disease